The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients
(2019) In Clinical Cancer Research 25(1). p.35-42- Abstract
Purpose: Previous studies using FLASH radiotherapy (RT) in mice showed a marked increase of the differential effect between normal tissue and tumors. To stimulate clinical transfer, we evaluated whether this effect could also occur in higher mammals. Experimental Design: Pig skin was used to investigate a potential difference in toxicity between irradiation delivered at an ultrahigh dose rate called "FLASH-RT" and irradiation delivered at a conventional dose rate called "Conv-RT." A clinical, phase I, single-dose escalation trial (25–41 Gy) was performed in 6 cat patients with locally advanced T2/T3N0M0 squamous cell carcinoma of the nasal planum to determine the maximal tolerated dose and progression-free survival (PFS) of single-dose... (More)
Purpose: Previous studies using FLASH radiotherapy (RT) in mice showed a marked increase of the differential effect between normal tissue and tumors. To stimulate clinical transfer, we evaluated whether this effect could also occur in higher mammals. Experimental Design: Pig skin was used to investigate a potential difference in toxicity between irradiation delivered at an ultrahigh dose rate called "FLASH-RT" and irradiation delivered at a conventional dose rate called "Conv-RT." A clinical, phase I, single-dose escalation trial (25–41 Gy) was performed in 6 cat patients with locally advanced T2/T3N0M0 squamous cell carcinoma of the nasal planum to determine the maximal tolerated dose and progression-free survival (PFS) of single-dose FLASH-RT. Results: Using, respectively, depilation and fibronecrosis as acute and late endpoints, a protective effect of FLASH-RT was observed (20% dose-equivalent difference vs. Conv-RT). Three cats experienced no acute toxicity, whereas 3 exhibited moderate/mild transient mucositis, and all cats had depilation. With a median follow-up of 13.5 months, the PFS at 16 months was 84%. Conclusions: Our results confirmed the potential advantage of FLASH-RT and provide a strong rationale for further evaluating FLASH-RT in human patients.
(Less)
- author
- publishing date
- 2019-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Cancer Research
- volume
- 25
- issue
- 1
- pages
- 8 pages
- publisher
- American Association for Cancer Research
- external identifiers
-
- pmid:29875213
- scopus:85052732901
- ISSN
- 1078-0432
- DOI
- 10.1158/1078-0432.CCR-17-3375
- language
- English
- LU publication?
- no
- additional info
- Publisher Copyright: © 2019 American Association for Cancer Research.
- id
- 15284bc6-4b81-47ab-8404-ffb6392e4be5
- date added to LUP
- 2021-11-03 18:17:21
- date last changed
- 2024-09-09 02:43:50
@article{15284bc6-4b81-47ab-8404-ffb6392e4be5, abstract = {{<p>Purpose: Previous studies using FLASH radiotherapy (RT) in mice showed a marked increase of the differential effect between normal tissue and tumors. To stimulate clinical transfer, we evaluated whether this effect could also occur in higher mammals. Experimental Design: Pig skin was used to investigate a potential difference in toxicity between irradiation delivered at an ultrahigh dose rate called "FLASH-RT" and irradiation delivered at a conventional dose rate called "Conv-RT." A clinical, phase I, single-dose escalation trial (25–41 Gy) was performed in 6 cat patients with locally advanced T2/T3N0M0 squamous cell carcinoma of the nasal planum to determine the maximal tolerated dose and progression-free survival (PFS) of single-dose FLASH-RT. Results: Using, respectively, depilation and fibronecrosis as acute and late endpoints, a protective effect of FLASH-RT was observed (20% dose-equivalent difference vs. Conv-RT). Three cats experienced no acute toxicity, whereas 3 exhibited moderate/mild transient mucositis, and all cats had depilation. With a median follow-up of 13.5 months, the PFS at 16 months was 84%. Conclusions: Our results confirmed the potential advantage of FLASH-RT and provide a strong rationale for further evaluating FLASH-RT in human patients.</p>}}, author = {{Vozenin, Marie Catherine and De Fornel, Pauline and Petersson, Kristoffer and Favaudon, Vincent and Jaccard, Maud and Germond, Jean François and Petit, Benoit and Burki, Marco and Ferrand, Gisele and Patin, David and Bouchaab, Hanan and Ozsahin, Mahmut and Bochud, François and Bailat, Claude and Devauchelle, Patrick and Bourhis, Jean}}, issn = {{1078-0432}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{35--42}}, publisher = {{American Association for Cancer Research}}, series = {{Clinical Cancer Research}}, title = {{The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients}}, url = {{http://dx.doi.org/10.1158/1078-0432.CCR-17-3375}}, doi = {{10.1158/1078-0432.CCR-17-3375}}, volume = {{25}}, year = {{2019}}, }